210 related articles for article (PubMed ID: 34789728)
1. Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.
Schenk MW; Humphrey S; Hossain ASMM; Revill M; Pearsall S; Lallo A; Brown S; Bratt S; Galvin M; Descamps T; Zhou C; Pearce SP; Priest L; Greenhalgh M; Chaturvedi A; Kerr A; Blackhall F; Dive C; Frese KK
Nat Commun; 2021 Nov; 12(1):6652. PubMed ID: 34789728
[TBL] [Abstract][Full Text] [Related]
2. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
3. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
El-Sehemy A; Chang AC; Azad AK; Gupta N; Xu Z; Steed H; Karsan A; Fu Y
Cell Signal; 2013 Dec; 25(12):2780-7. PubMed ID: 24041655
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
5. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.
Lim JS; Ibaseta A; Fischer MM; Cancilla B; O'Young G; Cristea S; Luca VC; Yang D; Jahchan NS; Hamard C; Antoine M; Wislez M; Kong C; Cain J; Liu YW; Kapoun AM; Garcia KC; Hoey T; Murriel CL; Sage J
Nature; 2017 May; 545(7654):360-364. PubMed ID: 28489825
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
8. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Yang X; Bai F; Xu Y; Chen Y; Chen L
Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
[TBL] [Abstract][Full Text] [Related]
9. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
10. Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Tunctan B; Korkmaz B; Sari AN; Kacan M; Unsal D; Serin MS; Buharalioglu CK; Sahan-Firat S; Cuez T; Schunck WH; Manthati VL; Falck JR; Malik KU
Nitric Oxide; 2013 Sep; 33():18-41. PubMed ID: 23684565
[TBL] [Abstract][Full Text] [Related]
11. The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Lallo A; Frese KK; Morrow CJ; Sloane R; Gulati S; Schenk MW; Trapani F; Simms N; Galvin M; Brown S; Hodgkinson CL; Priest L; Hughes A; Lai Z; Cadogan E; Khandelwal G; Simpson KL; Miller C; Blackhall F; O'Connor MJ; Dive C
Clin Cancer Res; 2018 Oct; 24(20):5153-5164. PubMed ID: 29941481
[No Abstract] [Full Text] [Related]
12. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.
Lallo A; Gulati S; Schenk MW; Khandelwal G; Berglund UW; Pateras IS; Chester CPE; Pham TM; Kalderen C; Frese KK; Gorgoulis VG; Miller C; Blackhall F; Helleday T; Dive C
Br J Pharmacol; 2019 Feb; 176(3):436-450. PubMed ID: 30427531
[TBL] [Abstract][Full Text] [Related]
14. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
15. Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
Cortese-Krott MM; Mergia E; Kramer CM; Lückstädt W; Yang J; Wolff G; Panknin C; Bracht T; Sitek B; Pernow J; Stasch JP; Feelisch M; Koesling D; Kelm M
Redox Biol; 2018 Apr; 14():328-337. PubMed ID: 29024896
[TBL] [Abstract][Full Text] [Related]
16. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
[TBL] [Abstract][Full Text] [Related]
17. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
19. FAK-LINC01089 negative regulatory loop controls chemoresistance and progression of small cell lung cancer.
Wang X; Li X; Niu L; Lv F; Guo T; Gao Y; Ran Y; Huang W; Wang B
Oncogene; 2024 May; 43(22):1669-1687. PubMed ID: 38594505
[TBL] [Abstract][Full Text] [Related]
20.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
